Linomide (BioDeep_00000183014)

   

human metabolite blood metabolite


代谢物信息卡片


N-Phenylmethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide

化学式: C18H16N2O3 (308.1160866)
中文名称: 利诺安
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN(C(=O)C1=C(O)C2=C(C=CC=C2)N(C)C1=O)C1=CC=CC=C1
InChI: InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3

描述信息

C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C1971 - Angiogenesis Activator Inhibitor
L - Antineoplastic and immunomodulating agents > L03 - Immunostimulants > L03A - Immunostimulants
D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents
D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors
D006133 - Growth Substances > D006131 - Growth Inhibitors
C308 - Immunotherapeutic Agent > C2139 - Immunostimulant
D007155 - Immunologic Factors

同义名列表

5 个代谢物同义名

N-Phenylmethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide; 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide; FCF-89LS-2616Linomide; Roquinimex; Linomide



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Zhi-Yong Xiao, Wen-Xia Zhou, Yong-Xiang Zhang, Jun-Ping Cheng, Jun-Feng He, Ri-Fang Yang, Liu-Hong Yun. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production. Life sciences. 2007 Oct; 81(19-20):1403-10. doi: 10.1016/j.lfs.2007.08.044. [PMID: 17950363]
  • Johanna Osterberg, Ulf Haglund. Effect of linomide on gut immune cell distribution and on TNF-alpha in plasma and ascites: an experimental study in the septic rat. Shock (Augusta, Ga.). 2002 Nov; 18(5):471-5. doi: 10.1097/00024382-200211000-00015. [PMID: 12412629]
  • J N Whitaker, J S Wolinsky, P A Narayana, A A Bartolucci, J H Noseworthy, F D Lublin, A Linde, P Gjörstrup, H C Sullivan. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Archives of neurology. 2001 Jan; 58(1):49-54. doi: 10.1001/archneur.58.1.49. [PMID: 11176936]
  • K Strandgården, P Höglund, L Grönquist, L Svensson, P O Gunnarsson. Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers. Biopharmaceutics & drug disposition. 2000 Mar; 21(2):53-67. doi: 10.1002/1099-081x(200003)21:2<53::aid-bdd214>3.0.co;2-f. [PMID: 11100907]
  • M Shalev, A Ko, M P Gelderman, E Fortin, G Reed, S Slavin, I Gery. Multiformic modulation of endotoxin effects by linomide. Clinical immunology (Orlando, Fla.). 1999 Dec; 93(3):250-5. doi: 10.1006/clim.1999.4800. [PMID: 10600336]
  • K Strandgârden, P Höglund, O Nordle, J Polacek, H Wännman, P O Gunnarsson. Dissolution rate-limited absorption and complete bioavailability of roquinimex in man. Biopharmaceutics & drug disposition. 1999 Oct; 20(7):347-54. doi: 10.1002/(sici)1099-081x(199910)20:7<347::aid-bdd194>3.0.co;2-0. [PMID: 10760843]
  • M Pollard. Prevention of prostate-related cancers in Lobund-Wistar rats. The Prostate. 1999 Jun; 39(4):305-9. doi: 10.1002/(sici)1097-0045(19990601)39:4<305::aid-pros12>3.0.co;2-y. [PMID: 10344221]
  • B Zbar, W Kaelin, E Maher, S Richard. Third International Meeting on von Hippel-Lindau disease. Cancer research. 1999 May; 59(9):2251-3. doi: NULL. [PMID: 10232616]
  • M Olausson, D Lukes, J Norrby, Z Qi, H Ekberg, G Gannedahl, G Tufveson, L Mjörnstedt. Antithymocyte globulin and cyclosporin A are synergistic in an experimental transplantation tolerance model in the rat. Scandinavian journal of immunology. 1999 Jan; 49(1):38-44. doi: 10.1046/j.1365-3083.1999.00453.x. [PMID: 10023855]
  • M J Mackean, D Kerr, M Lesko, A Svedberg, F Hansson, D Jodrell, J Cassidy. A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. British journal of cancer. 1998 Dec; 78(12):1620-3. doi: 10.1038/bjc.1998.732. [PMID: 9862573]
  • G del Real, M Llorente, L Boscá, S Hortelano, A Serrano, P Lucas, L Gómez, J L Torán, C Redondo, C Martínez. Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice. AIDS (London, England). 1998 May; 12(8):865-72. doi: 10.1097/00002030-199808000-00008. [PMID: 9631139]
  • O Pekarski, J Björk, G Hedlund, G Andersson. The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids. Autoimmunity. 1998; 28(4):235-41. doi: 10.3109/08916939808995371. [PMID: 9892505]
  • A C Harring, Z Xu, G Andersson, G Hedlund. Linomide enhances apoptosis in CD4+CD8+ thymocytes. Scandinavian journal of immunology. 1997 Nov; 46(5):488-94. doi: 10.1046/j.1365-3083.1997.d01-155.x. [PMID: 9393631]
  • D Lehmann, D Karussis, R Mizrachi-Koll, A S Linde, O Abramsky. Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. Clinical immunology and immunopathology. 1997 Nov; 85(2):202-9. doi: 10.1006/clin.1997.4444. [PMID: 9344704]
  • J Weidenfeld, D Karussis, O Abramsky, D Lehmann, I Arbell, H Ovadia. Linomide activates the adrenocortical axis in the rat: inhibition of experimental autoimmune encephalomyelitis by linomide is not related to the increase of corticosterone. Journal of neuroimmunology. 1997 Oct; 79(1):49-53. doi: 10.1016/s0165-5728(97)00121-5. [PMID: 9357446]
  • R de Wit, A Pawinsky, G Stoter, A T van Oosterom, S D Fosså, R Paridaens, A Svedberg, P H de Mulder. EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. European journal of cancer (Oxford, England : 1990). 1997 Mar; 33(3):493-5. doi: 10.1016/s0959-8049(97)89027-2. [PMID: 9155537]
  • A Pawinski, A T van Oosterom, R de Wit, S Fosså, J Croles, A Svedberg, M A Lentz, P H de Mulder. An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. European journal of cancer (Oxford, England : 1990). 1997 Mar; 33(3):496-9. doi: 10.1016/s0959-8049(97)89028-4. [PMID: 9155538]
  • S Hortelano, M J Díaz-Guerra, A Gonzalez-García, E Leonardo, C Gamallo, L Boscá, C Martínez-A. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr mice. Journal of immunology (Baltimore, Md. : 1950). 1997 Feb; 158(3):1402-8. doi: NULL. [PMID: 9013985]
  • J C Bergh, T H Tötterman, B C Termander, K A Strandgarden, P O Gunnarsson, B I Nilsson. The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects. Cancer investigation. 1997; 15(3):204-11. doi: 10.3109/07357909709039716. [PMID: 9171853]
  • S Morecki, C Nabet, P Falk, M Fridkis-Hareli, I Pecht, J J Mond, S Slavin. The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice. Autoimmunity. 1997; 25(4):223-32. doi: 10.3109/08916939708994731. [PMID: 9344330]
  • S Slavin, L Weiss, W Xia, D J Gross. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide). Cell transplantation. 1996 Nov; 5(6):627-30. doi: 10.1016/s0963-6897(96)00085-1. [PMID: 8951220]
  • M Deckert, A Franzke, J Buer, M Probst, S Duensing, E Lopez-Haenninen, H Kirchner, H Poliwoda, J Atzpodien. Linomide and interleukin-2 in patients with advanced renal cell carcinoma. Cancer biotherapy & radiopharmaceuticals. 1996 Oct; 11(5):319-24. doi: 10.1089/cbr.1996.11.319. [PMID: 10851512]
  • I B Joseph, J T Isaacs. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. The Prostate. 1996 Sep; 29(3):183-90. doi: 10.1002/(sici)1097-0045(199609)29:3<183::aid-pros4>3.0.co;2-f. [PMID: 8827087]
  • G Zandman-Goddard, J George, Y Levy, M Blank, S Slavin, Y Shoenfeld. Modulation of experimental systemic lupus erythematosus with linomide. Lupus. 1996 Aug; 5(4):328-33. doi: 10.1177/096120339600500415. [PMID: 8869907]
  • U B Christensen, D Mauricio, J I Reimers, H U Andersen, T Kalland, J Nerup, T Mandrup-Poulsen. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on beta-cells in vivo or ex vivo. Autoimmunity. 1996; 23(4):257-68. doi: 10.3109/08916939608995348. [PMID: 8915032]
  • M Olausson, N Arvidsson, D Lukes, L Mjörnstedt, Z Qi, H Ekberg, G Gannedahl, G Tufveson. Inhibition of ATG-induced experimental transplantation tolerance with LS2616. Transplantation proceedings. 1995 Dec; 27(6):3541-3. doi: NULL. [PMID: 8540092]
  • J Vukanovic, B Hartley-Asp, J T Isaacs. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. The Prostate. 1995 May; 26(5):235-46. doi: 10.1002/pros.2990260503. [PMID: 7538663]
  • J Vukanovic, J T Isaacs. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer research. 1995 Apr; 55(7):1499-504. doi: NULL. [PMID: 7533663]
  • D M Karussis, D Lehmann, T Brenner, I Wirguin, R Mizrachi-Koll, C Sicsic, O Abramsky. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. Journal of neuroimmunology. 1994 Dec; 55(2):187-93. doi: 10.1016/0165-5728(94)90009-4. [PMID: 7829669]
  • P Borgström, I P Torres Filho, P Vajkoczy, K Strandgården, J Polaçek, B Hartley-Asp. The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer chemotherapy and pharmacology. 1994; 34(4):280-6. doi: 10.1007/bf00686033. [PMID: 7518359]
  • N G Ilbäck, L Wesslén, K Pauksen, T Stålhandske, G Friman, J Fohlman. Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease. Scandinavian journal of infectious diseases. Supplementum. 1993; 88(?):117-23. doi: . [PMID: 8390714]
  • A Wanders, P Vogt, A Karlsson-Parra, K Wonigkeit, B Gerdin, G Tufveson. Evidence that LS-2616 (linomide) causes acute rejection of rat allografts protected by cyclosporine but not of long-term surviving allografts. Transplantation. 1991 Aug; 52(2):234-8. doi: 10.1097/00007890-199108000-00010. [PMID: 1871795]
  • S Kleinau, P Larsson, J Björk, R Holmdahl, L Klareskog. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clinical and experimental immunology. 1989 Oct; 78(1):138-42. doi: NULL. [PMID: 2805418]
  • A L Spetz-Hagberg, E L Larsson-Sciard. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after linomide treatment. Research in immunology. 1989 Jun; 140(5-6):517-25. doi: 10.1016/0923-2494(89)90117-x. [PMID: 2789418]
  • T Stålhandske, T Kalland. Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology. 1986 Apr; 11(2):87-92. doi: 10.1016/0162-3109(86)90028-7. [PMID: 2872188]
  • T Kalland, G Alm, T Stålhandshe. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. Journal of immunology (Baltimore, Md. : 1950). 1985 Jun; 134(6):3956-61. doi: NULL. [PMID: 2580900]